ストックスクリーナーアプリを入手
2.60
0.38%
-0.010
アフターアワーズ：
2.61
0.010
+0.38%
前日終値:
$2.61
開ける：
$2.64
24時間の取引高:
17,113
Relative Volume:
0.19
時価総額：
$27.91M
収益：
$66.38M
当期純損益:
$-14.18M
株価収益率:
-0.9261
EPS:
-2.8074
ネットキャッシュフロー:
$-5.17M
1週間 パフォーマンス:
-1.52%
1か月 パフォーマンス:
+12.55%
6か月 パフォーマンス:
+14.04%
1年 パフォーマンス:
+106.35%
1日の値動き範囲:
$2.58
$2.655
1週間の範囲:
$2.37
$2.68
52週間の値動き範囲:
$0.95
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Compare AYTU vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.60 | 28.01M | 66.38M | -14.18M | -5.17M | -2.8074 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.09B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
120.49 | 51.65B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.17 | 45.70B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.52 | 36.69B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
535.81 | 23.19B | 3.13B | 1.27B | 1.12B | 26.39 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-01 | 開始されました | Lake Street | Buy |
| 2025-06-30 | 開始されました | Ascendiant Capital Markets | Buy |
| 2021-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 開始されました | H.C. Wainwright | Buy |
Aytu Biopharma Inc (AYTU) 最新ニュース
Will Aytu BioPharma Inc. stock deliver consistent dividendsJuly 2025 Levels & Consistent Growth Stock Picks - Naître et grandir
Aug Outlook: Will Aytu BioPharma Inc benefit from rising consumer demandJuly 2025 Technicals & Fast Gain Swing Alerts - baoquankhu1.vn
Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research - Defense World
AYTU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aytu BioPharma, Inc. (AYTU) Competitors - Meyka
Is Aytu BioPharma Inc. forming a double bottomGlobal Markets & Intraday High Probability Alerts - mfd.ru
Is Aytu BioPharma Inc. stock a good pick for beginnersJuly 2025 Momentum & Low Risk High Win Rate Stock Picks - mfd.ru
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lytton, foundation report 9.99% Aytu BioPharma (AYTU) stake - Stock Titan
What is the cash position of Aytu BioPharma Inc.2025 Trading Recap & AI Forecasted Entry and Exit Points - mfd.ru
Panic Selling: What analysts say about Aytu BioPharma Inc stockMarket Trend Review & Safe Entry Zone Tips - baoquankhu1.vn
Breakouts Watch: What analysts say about Aytu BioPharma Inc stockMarket Risk Summary & High Accuracy Investment Signals - baoquankhu1.vn
Pharma News: Is Aytu BioPharma Inc. (AY20) stock testing key support2025 Trading Recap & Long-Term Capital Growth Strategies - mfd.ru
Will Aytu BioPharma Inc. (AY20) stock benefit from infrastructure billRisk Management & Consistent Growth Stock Picks - mfd.ru
Is Aytu BioPharma Inc. a strong candidate for buy and hold2025 Macro Impact & Short-Term High Return Ideas - mfd.ru
How Aytu BioPharma Inc. (AY20) stock gains from tech spendingGlobal Markets & Advanced Technical Analysis Signals - mfd.ru
Will Aytu BioPharma Inc. outperform tech stocksShare Buyback & Smart Allocation Stock Tips - mfd.ru
Will Aytu BioPharma Inc. benefit from rising consumer demandJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - mfd.ru
Lake Street Remains a Buy on Aytu BioScience (AYTU) - The Globe and Mail
Aytu BioPharma Insider Buyers Net US$87k Despite 10% Stock Decline - simplywall.st
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit - Yahoo Finance
Aytu BioPharma Q2 Earnings Call Highlights - Defense World
Aytu BioPharma AYTU Q2 2026 Earnings Transcript - AOL.com
Full Transcript: Aytu BioPharma Q2 2026 Earnings Call - Benzinga
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 Earnings Call Transcript - Insider Monkey
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navi - GuruFocus
Earnings call transcript: Aytu BioPharma Q2 2026 sees revenue dip, stock falls - Investing.com Nigeria
Aytu BioPharma Inc (NASDAQ:AYTU) Posts Q2 Revenue Beat Amid EXXUA Launch Costs - ChartMill
AYTU: Exxua launch drives early momentum; net revenue $15.2M, net loss $10.6M on launch costs - TradingView
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
AYTU Reports Q2 Revenue Decline Amid Shift to New Product Launch - GuruFocus
Aytu BioPharma Q2 Earnings Summary & Key Takeaways - Benzinga
Aytu BioPharma Q2 Earnings Assessment - Benzinga
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results - ACCESS Newswire
Earnings To Watch: Aytu BioPharma Inc (AYTU) Reports Q2 2026 Res - GuruFocus
New Strong Sell Stocks for February 2nd - Nasdaq
Earnings Recap: Is Aytu BioPharma Inc stock influenced by commodity pricesProduct Launch & Weekly Market Pulse Alerts - baoquankhu1.vn
Gainers Report: Will Aytu BioPharma Inc stock benefit from M A2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 - ACCESS Newswire
Pharma News: Will Aytu BioPharma Inc benefit from rising consumer demandQuarterly Market Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Aytu launches EXXUA, first selective 5-HT1A agonist for depression By Investing.com - Investing.com South Africa
Aytu BioPharma Highlights EXXUA Opportunity at Investor Day - TipRanks
Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - ACCESS Newswire
Aytu BioPharma Recaps Investor Day and EXXUA Launch - TradingView
New EXXUA depression drug targets MDD without sexual side effects - Stock Titan
AYTU: Exxua launches as a differentiated MDD therapy, targeting growth with disciplined, scalable execution - TradingView
AYTU: Exxua launches as a novel MDD therapy, targeting unmet needs with strong financial discipline - TradingView
Aytu launches EXXUA, first selective 5-HT1A agonist for depression - Investing.com
Aytu BioPharma (AYTU) Launches EXXUA for Treating Major Depressi - GuruFocus
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Di - PharmiWeb.com
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA - ACCESS Newswire
Aytu Biopharma Inc (AYTU) 財務データ
収益
当期純利益
現金流量
EPS
1.13%
0.83%
大文字化:
|
ボリューム (24 時間):